<DOC>
	<DOCNO>NCT00829660</DOCNO>
	<brief_summary>The purpose study determine whether acarbose therapy reduce cardiovascular-related morbidity mortality patient impair glucose tolerance ( IGT ) establish coronary heart disease ( CHD ) acute coronary syndrome ( ACS ) . A secondary objective study determine acarbose therapy prevent delay transition type 2 diabetes mellitus ( T2DM ) patient population .</brief_summary>
	<brief_title>Acarbose Cardiovascular Evaluation Trial</brief_title>
	<detailed_description>A long-term , multicentre , double-blind , randomise parallel-group trial determine whether reduce post-prandial glycaemia reduce cardiovascular-related morbidity mortality patient establish coronary heart disease acute coronary syndrome impair glucose tolerance .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<criteria>Male female , age 50 year . Definite CHD , define , b c : 1 . Previous myocardial infarction ( MI ) Acute Coronary Syndrome ( ACS ) , within last 3 month , two following : Typical clinical presentation Confirmatory ECG change Appropriate elevation cardiac enzymes/biomarkers 2 . Previous unstable angina ( UA ) Acute Coronary Syndrome ( ACS ) , within last 3 month , two following : Typical clinical presentation Confirmatory ECG change Either elevation cardiac biomarker &gt; 50 % stenosis ≥1 major epicardial coronary artery show coronary angiography CT angiography . Where stenosis report qualitative manner , categories `` moderate '' `` severe '' take equate &gt; 50 % stenosis . 3 . Current stable angina define : Typical clinical history symptom occur within last month , A &gt; 50 % stenosis ≥1 major epicardial coronary artery show coronary angiography CT angiography . Where stenosis report qualitative manner , categories `` moderate '' `` severe '' take equate &gt; 50 % stenosis . Impaired glucose tolerance diagnose single standard OGTT , define 2hour plasma glucose ( 2HPG ) value ≥7.8 &lt; 11.1 mmol/l fast plasma glucose ( FPG ) &lt; 7.0 mmol/l within six month prior enrollment . Optimised cardiovascular drug therapy . At least 80 % adherent single blind placebo Study Medication runin period . Provision write informed consent . Previous history diabetes , gestational diabetes . MI , unstable angina , stroke transient ischaemic attack ( TIA ) within previous three month . Planned anticipated coronary , cerebrovascular peripheral arterial revascularisation major surgical intervention . NYHA class III IV heart failure . Evidence severe hepatic disease . Evidence severe renal impairment eGFR &lt; 30 ml/min/1.73m2 ( derive use MDRD Chinese equation ) Any condition likely reduce adherence protocol e.g . alcoholism , major active psychiatric disorder , cognitive impairment condition likely markedly limit life expectancy e.g . malignancy . Pregnancy ( plan pregnancy within next five year ) . Concurrent participation clinical interventional trial . Known intolerance alpha glucosidase inhibitor gastrointestinal problem . Thought investigator reason unsuitable participation clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Acarbose</keyword>
</DOC>